Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Front Endocrinol (Lausanne) ; 12: 611526, 2021.
Article in English | MEDLINE | ID: covidwho-1305635

ABSTRACT

Background: It has been reported that dyslipidemia is related to coronavirus-related diseases. Critical patients with coronavirus disease 2019 (COVID-19) who suffered from multiple organ dysfunctions were treated in the intensive care unit (ICU) in Wuhan, China. Whether the lipids profile was associated with the prognosis of COVID-19 in critical patients remained unclear. Methods: A retrospective study was performed in critical patients (N=48) with coronavirus disease 2019 in Leishenshan hospital between February and April 2020 in Wuhan. The parameters including lipid profiles, liver function, and renal function were collected on admission day, 2-3days after the admission, and the day before the achievement of clinical outcome. Results: Albumin value and creatine kinase (ck) value were statistically decreased at 2-3 days after admission compared with those on admission day (P<0.05). Low density lipoprotein (LDL-c), high density lipoprotein (HDL-c), apolipoprotein A (ApoA), and apolipoprotein A (Apo B) levels were statistically decreased after admission (P<0.05). Logistic regression showed that HDL-c level both on admission day and the day before the achievement of clinical outcome were negatively associated with mortality in critical patients with COVID-19. Total cholesterol (TC) level at 2-3days after admission was related to mortality in critical patients with COVID-19. Conclusions: There were lipid metabolic disorders in the critical patients with COVID-19. Lower levels of HDL-c and TC were related to the progression of critical COVID-19.


Subject(s)
COVID-19/mortality , Dyslipidemias/epidemiology , Hospital Mortality , Multiple Organ Failure/mortality , Aged , Aged, 80 and over , Apolipoproteins A/blood , Apolipoproteins B/blood , COVID-19/blood , COVID-19/epidemiology , China/epidemiology , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Critical Illness , Dyslipidemias/blood , Female , Humans , Male , Middle Aged , Multiple Organ Failure/blood , Multiple Organ Failure/epidemiology , Retrospective Studies , Risk Factors , SARS-CoV-2 , Severity of Illness Index
2.
medrxiv; 2021.
Preprint in English | medRxiv | ID: ppzbmed-10.1101.2021.06.16.21258808

ABSTRACT

Abstract Background The COVID-19 vaccine is an essential means to establish group immunity and prevent the spread of the pandemic. However, the public's hesitation has created major difficulties to the promotion of the vaccine. By investigating the relationship between health literacy and COVID-19 vaccine hesitancy, as well as the potential moderating role of stress, the present study would provide critical insights for tailoring vaccine-promotion strategies. Objective The two-fold research purpose is: i) address the effect of health literacy on people's attitude toward COVID-19 vaccine, ii) clarify the role of stress in this effect. Method With structured questionnaires, an online survey was conducted to evaluate general public's COVID-19 vaccine hesitancy, health literacy, and perceived stress. In total, 560 responses were collected, and moderated regression analysis was conducted to test the effect of health literacy on vaccine hesitancy among people with different levels of stress. Results A total of 560 participants aged over 18 years were included in this study. About 39.8% of the respondents reported vaccine hesitancy, and this rate is higher among those aged 20-30 years old (83%) and female (71.3%). The results showed people with higher level of health literacy are less likely to have vaccine hesitancy . However, this effect was only among those with lower to moderate level of stress , among the people with high stress, no significant effect of health literacy was found . Conclusions By focusing on the effect of health literacy on COVID-19 vaccine hesitancy, the findings showed education program increasing individual's health literacy may also effectively reduce the public's vaccine hesitancy and promote accepting attitude. However, for people with high level of stress, other health programs need to be developed to enhance their positive attitude toward the COVID-19 vaccine. In conclusion, promotion strategies should be tailored for different populations, with considering individual factors such as health literacy and stress. Keywords vaccine hesitancy; health literacy; stress; moderation


Subject(s)
COVID-19
3.
EClinicalMedicine ; 34: 100831, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1184949

ABSTRACT

BACKGROUND: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children is associated with better outcomes than in adults. The inflammatory response to COVID-19 infection in children remains poorly characterised. METHODS: We retrospectively analysed the medical records of 127 laboratory-confirmed COVID-19 patients aged 1 month to 16 years from Wuhan and Jingzhou of Hubei Province. Patients presented between January 25th and March 24th 2020. Information on clinical features, laboratory results, plasma cytokines/chemokines and lymphocyte subsets were analysed. FINDINGS: Children admitted to hospital with COVID-19 were more likely to be male (67.7%) and the median age was 7.3 [IQR 4.9] years. All but one patient with severe disease was aged under 2 and the majority (5/7) had significant co-morbidities. Despite 53% having viral pneumonia on computed tomography (CT) scanning only 2 patients had low lymphocyte counts and no differences were observed in the levels of plasma proinflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, tumour necrosis factor (TNF)- α , and interferon (IFN)- γ between patients with mild, moderate or severe disease. INTERPRETATIONS: We observed that the immune responses of children to COVID-19 infection is significantly different from that seen in adults. Our evidence suggests that SARS-CoV-2 does not trigger a robust inflammatory response or 'cytokine storm' in children with COVID-19, and this may underlie the generally better outcomes seen in children with this disease.

4.
BMJ Open ; 10(12): e044028, 2020 12 24.
Article in English | MEDLINE | ID: covidwho-999261

ABSTRACT

OBJECTIVE: This study aimed to develop and externally validate a COVID-19 mortality risk prediction algorithm. DESIGN: Retrospective cohort study. SETTING: Five designated tertiary hospitals for COVID-19 in Hubei province, China. PARTICIPANTS: We routinely collected medical data of 1364 confirmed adult patients with COVID-19 between 8 January and 19 March 2020. Among them, 1088 patients from two designated hospitals in Wuhan were used to develop the prognostic model, and 276 patients from three hospitals outside Wuhan were used for external validation. All patients were followed up for a maximal of 60 days after the diagnosis of COVID-19. METHODS: The model discrimination was assessed by the area under the receiver operating characteristic curve (AUC) and Somers' D test, and calibration was examined by the calibration plot. Decision curve analysis was conducted. MAIN OUTCOME MEASURES: The primary outcome was all-cause mortality within 60 days after the diagnosis of COVID-19. RESULTS: The full model included seven predictors of age, respiratory failure, white cell count, lymphocytes, platelets, D-dimer and lactate dehydrogenase. The simple model contained five indicators of age, respiratory failure, coronary heart disease, renal failure and heart failure. After cross-validation, the AUC statistics based on derivation cohort were 0.96 (95% CI, 0.96 to 0.97) for the full model and 0.92 (95% CI, 0.89 to 0.95) for the simple model. The AUC statistics based on the external validation cohort were 0.97 (95% CI, 0.96 to 0.98) for the full model and 0.88 (95% CI, 0.80 to 0.96) for the simple model. Good calibration accuracy of these two models was found in the derivation and validation cohort. CONCLUSION: The prediction models showed good model performance in identifying patients with COVID-19 with a high risk of death in 60 days. It may be useful for acute risk classification. WEB CALCULATOR: We provided a freely accessible web calculator (https://www.whuyijia.com/).


Subject(s)
Algorithms , COVID-19/mortality , Hospitalization/statistics & numerical data , Pandemics , Risk Assessment/methods , SARS-CoV-2 , COVID-19/therapy , China/epidemiology , Follow-Up Studies , Humans , Prognosis , ROC Curve , Retrospective Studies , Risk Factors , Survival Rate/trends
5.
J Clin Lab Anal ; 35(1): e23644, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-893229

ABSTRACT

OBJECTIVES: To investigate laboratory markers for COVID-19 progression in patients with different medical conditions. METHODS: We performed a multicenter retrospective study of 836 cases in Hubei. To avoid the collinearity among the indicators, principal component analysis (PCA) followed by partial least squares discriminant analysis (PLS-DA) was performed to obtain an overview of laboratory assessments. Multivariable logistic regression analysis and multivariable Cox proportional hazards regression analysis were respectively used to explore risk factors associated with disease severity and mortality. Survival analysis was performed in patients with the most common comorbidities. RESULTS: Lactate dehydrogenase (LDH) and prealbumin were associated with disease severity in patients with or without comorbidities, indicated by both PCA/PLS-DA and multivariable logistic regression analysis. The mortality risk was associated with age, LDH, C-reactive protein (CRP), D-dimer, and lymphopenia in patients with comorbidities. CRP was a risk factor associated with short-term mortality in patients with hypertension, but not liver diseases; additionally, D-dimer was a risk factor for death in patients with liver diseases. CONCLUSIONS: Lactate dehydrogenase was a reliable predictor associated with COVID-19 severity and mortality in patients with different medical conditions. Laboratory biomarkers for mortality risk were not identical in patients with comorbidities, suggesting multiple pathophysiological mechanisms following COVID-19 infection.


Subject(s)
Biomarkers/blood , COVID-19/etiology , Adult , Aged , C-Reactive Protein/analysis , COVID-19/epidemiology , Comorbidity , Diabetes Mellitus/epidemiology , Disease Progression , Female , Hospitalization/statistics & numerical data , Humans , Hypertension/epidemiology , L-Lactate Dehydrogenase/blood , Least-Squares Analysis , Liver Diseases/epidemiology , Male , Middle Aged , Prealbumin/analysis , Principal Component Analysis , Retrospective Studies , Survival Rate
6.
Intern Emerg Med ; 16(4): 853-862, 2021 06.
Article in English | MEDLINE | ID: covidwho-871549

ABSTRACT

BACKGROUND: The worldwide spread of SARS-CoV-2 has infected millions of people leading to over 0.3 million mortalities. The disruption of sodium homeostasis, tends to be a common occurrence in patients with COVID-19. METHODS AND RESULTS: A total of 1,254 COVID-19 patients comprising 124 (9.9%) hyponatremic patients (under 135 mmol/L) and 30 (2.4%) hypernatremic patients (over 145 mmol/L) from three hospitals in Hubei, China, were enrolled in the study. The relationships between sodium balance disorders in COVID-19 patients, its clinical features, implications, and the underlying causes were presented. Hyponatremia patients were observed to be elderly, had more comorbidities, with severe pneumonic chest radiographic findings. They were also more likely to have a fever, nausea, higher leukocyte and neutrophils count, and a high sensitivity C-reactive protein (HS-CRP). Compared to normonatremia patients, renal insufficiency was common in both hyponatremia and hypernatremia patients. In addition, hyponatremia patients required extensive treatment with oxygen, antibiotics, and corticosteroids. The only significant differences between the hypernatremia and normonatremia patients were laboratory findings and clinical complications, and patients with hypernatremia were more likely to use traditional Chinese medicine for treatment compared to normonatremia patients. This study indicates that severity of the disease, the length of stay in the hospital of surviving patients, and mortality were higher among COVID-19 patients with sodium balance disorders. CONCLUSION: Sodium balance disorder, particularly hyponatremia, is a common condition among hospitalized patients with COVID-19 in Hubei, China, and it is associated with a higher risk of severe illness and increased in-hospital mortality.


Subject(s)
COVID-19/complications , Hypernatremia/epidemiology , Hyponatremia/epidemiology , Adult , Aged , Aged, 80 and over , COVID-19/diagnosis , COVID-19/mortality , China , Female , Hospital Mortality , Hospitalization , Humans , Hypernatremia/diagnosis , Hypernatremia/therapy , Hyponatremia/diagnosis , Hyponatremia/therapy , Male , Middle Aged , Retrospective Studies , Young Adult
7.
Journal of Hazardous Materials ; 401:123292-123292, 2020.
Article in English | MEDLINE | ID: covidwho-662308

ABSTRACT

Herein, a high-performance porous biochar described as PBCKOH was successfully synthesized by two-step pyrolysis of corn straw with chemical activation of KOH, and was employed for the elimination of Cr(VI) and naphthalene (NAP) from water. Benefiting from KOH activation, the PBCKOH was found to possess huge specific surface area of 2183.80 m2/g and many well-developed micropores with average particle size of 2.75 nm and main pore diameters distribution from 1 to 2 nm. The PBCKOH presented an excellent adsorption performance with a theoretical monolayer uptake of 116.97 mg/g for Cr(VI) and a heterogeneous adsorption capacity of 450.43 mg/g for NAP. The uptake equilibrium was attained within about 120 min for Cr(VI), while about 180 min for NAP following avrami fractional-order model, revealing the existence of multiple kinetics during the adsorption. The thermodynamic results showed that the uptake of both Cr(VI) and NAP occurred spontaneously (-ΔG°), while in an endothermic nature for Cr(VI) (+ΔH°) and an exothermic characteristic for NAP (-ΔH°) with different randomness. Furthermore, the PBCKOH was believed to enhance the Cr(VI) adsorption mainly through the combination of electrostatic attraction, complexation, ion exchange and reduction action, while achieving the high NAP uptake by pore filling and π-πstacking interactions.

8.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-64083.v1

ABSTRACT

Background Novel coronavirus disease (COVID-19) is an emerging, rapidly evolving situation. At present, the prognosis of severe and critically ill patients has become an important focus of attention. We strived to develop a prognostic prediction model for severe and critically ill COVID-19 patients.MethodsTo assess the factors associated with the prognosis of those patients, we retrospectively investigated the clinical, laboratory characteristics of confirmed 112 cases of COVID-19 admitted between 21 January to 6 March 2020 from Huangshi Central Hospital, Huangshi Hospital of Traditional Chinese Medicine, and Daye People’s Hospital. We applied machine learning method (survival random forest) to select predictors for 28-day survival and taken into account the dynamic trajectory of laboratory indicators. Results Fifteen candidate prognostic features, including 11 baseline measures (including platelet count (PLT), urea, creatine kinase (CK), fibrinogen, creatine kinase isoenzyme activity, aspartate aminotransferase (AST), activation of partial thromboplastin time (APTT), albumin, standard deviation of erythrocyte distribution width (RBC-SD), neutrophils (%) and red blood cell count (RBC)) and 4 trajectory clusters (changes during hospitalization in the white blood cell (WBC), PLT large cell ratio (P-LCR), PLT distribution width (PDW) and AST), combined with covariates achieved 100% (95%CI: 99%-100%) AUC and reached 87% (95%CI: 84%-91%) AUC in an external validation set. Conclusions Taking advantage of random forest technique and laboratory dynamic measures, we developed a forest model to predict survival outcome of COVID-19 patients, which achieved 87% AUC in the external validation set. Our online tool will help to facilitate the early recognition of patients with high risk. 


Subject(s)
Coronavirus Infections , Critical Illness , COVID-19
9.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-51823.v1

ABSTRACT

Background: The aim of this study was to investigate the experience of the combination of remote learning and virtual microscopy in oral histopathology teaching, a unique experience in China in response to the Covid-19 pandemic.Methods: 192 third-year dental students were recruited to participate in the course independently on the E-learning platform and Virtual Simulation Experiment Teaching Center of Stomatology of Nanjing Medical University. A questionnaire survey explored students' satisfaction with the education. Differences of assessment results among different groups were compared using Mann-Whitney U and independent-sample T tests.Results:The mean Theory test scores of the Online group (80.93±12.15) were significantly higher than those of the Traditional group (73.65±8.46) (P < 0.01). The mean total scores of the Online group (82.94±10.76) were significantly higher than those of the Traditional group (77.25±7.55) (P < 0.01). The percentage of high total test score (test score > 85) of the Online group (54%) was also significantly higher than that of the Traditional group (15%) (P< 0.01). Furthermore, both remote learning and virtual microscopy courses were well accepted by students according to the questionnaire. Conclusions: The application of remote learning and virtual microscopy have enhanced oral histopathology teaching in China in response to the Covid-19 pandemic.


Subject(s)
COVID-19
10.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-34267.v1

ABSTRACT

Background: An outbreak caused by the 2019 novel coronavirus (2019-nCoV) has spread globally. However, the viral dynamics, co-infection and their associations with clinical severity, have not been well explored.Methods: We longitudinally enrolled 23 (Five severe-type, ten common-type and eight asymptomatic-type patients) hospitalized 2019-nCov-infected patients in Jiangsu between January 21 and February 11, 2020. Medical records and pharyngeal swab specimens, were collected to analyze the association between viral dynamic and disease severity.Results: Five severe-type, ten common-type and eight asymptomatic-type patients were enrolled. Linear mixed effects models revealed that the common and severe-type patients had a higher level of viral load (3.08 points, 95% CI, 0.51-5.65, P = 0.019; 6.07 points, 95% CI, 2.79-9.35, P < 0.001) and maintained a higher peak viral load ( P = 0.066 and 0.022, respectively), when compared with the asymptomatic group. Viral load shedding among older patients (aged ≥ 60) processed slower than that among younger patients ( P = 0.047). RNA virome sequencing identified two co-infected RNA viruses, Human endogenous retrovirus H (HERV) and Human picobirnavirus (HPBV). Of note, HPBV was detected in one severe-type and two common-type patients, while was not detected in all the asymptomatic cases.Conclusion: Higher viral load was positively associated with disease severity. This finding highlights the importance of monitoring the viral kinetics to identify patients at greater risk of progressing to severe pneumonia.


Subject(s)
COVID-19 , Coinfection , Pneumonia
11.
researchsquare; 2020.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-25040.v1

ABSTRACT

Background The World Health Organization characterized the 2019 novel coronavirus disease (COVID-19) as a pandemic on March 11. Many clinical trials on COVID-19 have been registered, and we aim to review the characteristics of the trials and provide guidance for future trials to avoid duplicated effort.Methods All the studies on COVID-19 registered before Mar 3, 2020 on eight registry platforms worldwide were searched and the data of design, participants, interventions, and outcomes were extracted and analyzed. The most promising trials were screened based on study design, rationale, and resource availability.Results 393 studies registered were identified until Mar 3 2020 and 380 (96.7%) studies were from mainland China, while 3 in Japan, 3 in France, 2 in the US, and 3 were international collaborative studies. 363 studies (92.4%) recruited participants from hospitals and 266 studies (67.7%) aimed at therapeutic effect, others were for prevention, diagnosis, prognosis, etc. 202 studies (51.4%) were randomized controlled trials (RCTs). The average sample size was 1061 and ranged from 8 to 150,000 per study. 177 out of 266 therapeutic studies (66.5% ) tested Western medicines including antiviral drugs (17.7%), stem cell and cord blood therapy (10.2%), chloroquine and derivatives (8.3%), 16 (6.0%) on Chinese medicines, and 73 (27.4%) on integrated therapy of Western and Chinese medicines. 14 Chinese medicines had its clear rationale for evaluation of therapeutic effects. 31 studies among 266 therapeutic studies (11.7%) used mortality as primary outcome, while the most designed secondary outcomes were symptoms and signs (47.0%). 106 studies (27.0%) were funded by the government, and 268 (68.2%) demonstrated ethical approval. 45.5% studies (179 out of 266) had not started recruiting till Mar 3. Eight RCTs were evaluated as the most promising trials.Conclusions Majority of the studies focused on assessing therapeutics for COVID-19 but inappropriate outcome setting, delayed recruitment and insufficient numbers of new cases in China implied many studies may fail to complete. Strategies and protocols of the studies with robust and rapid data sharing from international collaboration are warranted for emergency public health events, helping to accelerate priority setting for timely evidence-based decision-making.


Subject(s)
COVID-19
SELECTION OF CITATIONS
SEARCH DETAIL